You are here: Industry Insights > Market News > Granules India gets board nod to raise foreign investment limit

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

Granules India gets board nod to raise foreign investment limit

expressbpdJuly 06, 2017

Tag: granules india , foreign investment limit

Favorites

Granules India said its board has approved a proposal to increase the foreign investment limit in the company to 49 per cent.

The board of directors has agreed to increase the present limit of FII/ FPIs shareholding in the company to 49 per cent of the total paid-up equity share capital, Granules India said in a BSE filing.

However, it said, the decision would be subject to shareholders’ approval.

As on March 31, 2017, FPI holding in the company stood at 9.98 per cent. Other foreign nationals owned 0.06 per cent.

Previous:Lupin launches generic Vigamox Ophthalmic solution in the US

Next:A new highly innovative approach for tackling antimicrobial drug resistance – calorimetry has arrive

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Granules India gets board nod to raise foreign investment limit | Pharmasources.com

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .

Granules India gets board nod to raise foreign investment limit

Related News

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

You may like
More>>

Granules India gets board nod to raise foreign investment limit

Related News

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

You may likeMore>>

You may like
More>>